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The Brazilian private pharmaceutical market
after the first ten years of the generics law
Andréa Dâmaso Bertoldi1* , Anita K. Wagner2, Isabel Cristina Martins Emmerick3, Luisa Arueira Chaves4,
Peter Stephens5 and Dennis Ross-Degnan2
Abstract
Objectives: To describe changes in the private market for selected originators, branded generics (‘similares’), and
generic products during the 10 years following passage of the Brazilian Generics Law.
Methods: We analyzed longitudinal data collected by IQVIA® on quarterly sales by wholesalers to retail
pharmacies in Brazil from 1998 through 2010, grouped by originators, branded generics, and generic products
in three therapeutic classes (antibiotics, antidiabetics, and antihypertensives). Outcomes included market share
(proportion of the total private market volume), sales volume per capita, prices and number of manufacturers
by group.
Results: In the private market share, generics became dominant in each therapeutic class but the speed of
uptake varied. Originators consistently lost most market share while branded generics varied over time. By the
end of the study period, generics were the most sold product type in all classes, followed by branded
generics. The number of generic manufacturers increased in all classes, while branded generics increased just
after the policy but then decreased slowly through the end of 2010. For approximately 50% of the antibiotics
analyzed, branded generics and generics had lower prices than originators. For antidiabetics, branded generic
and generic prices were quite similar during the period analyzed. Price trends for the various subclasses of
antihypertensive exhibited very different patterns over time.
Conclusion: Sales of branded generics and originators decreased substantially in the three therapeutic classes
analysed following the introduction of the generics policy in Brazil, but the time to market dominance of
generics varied by class.
Keywords: Generic medicines; pharmaceutical policy, Market share, Prices, Brazil
Introduction
The World Health Organization considers equitable
access to safe and affordable medicines as vital to the
attainment of the highest possible standard of health by
all [1, 2]. Strategies aimed at improving access to essen-
tial medicines have been adopted in many countries. Of
special relevance are strategies that aim to guarantee
not only the availability of medicines [1]. Despite those
initiatives, access to medicines remains an important
issue to be addressed in low and middle-income
countries, where out-of-pocket expenditures for medi-
cines are an important economic burden [3].
In Brazil, access to health care and medicines is
recognized as a citizen’s constitutional right and the
government’s responsibility [4]. The Unified Health
System (SUS – ‘Sistema Único de Saúde’) provides
free of charge all medicines, which are part of the na-
tional list of essential medicines (RENAME – ‘Relação
Nacional de Medicamentos Essenciais’). However, low
availability in the public sector leads to high
out-of-pocket expenditures for medicines in the pri-
vate sector [5]. Data from the household expenditures
survey shows that, with 47% of total household
expenditures, health care accounts for the fourth
most important group of expenses, with a greater
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burden among the poorest [6]. Although the major-
ity of the Brazilian population uses SUS, around 27%
of all households pay for private health insurance
[7], which in Brazil usually does not cover outpatient
medicines [8]. Increasing the affordability of medi-
cines is a key goal of Brazilian health policy [3, 8].
Ensuring access to medicines is especially relevant
among the poorest population. The catastrophic
health expenditure in Brazil between 2002–2003 and
2008–2009 increased significantly, becoming 5.20
times higher among the poorest [9].
The Brazilian pharmaceutical market is one of the
worldwide leaders in terms of total expenditures [10,
11], which is a consequence of the size of the coun-
try, characteristics of the market, and pharmaceutical
policies. Some regulatory action by the Brazilian
government guide the first 10 years of implantation of
the generics Law. First, the generics Law and second,
the regulation of controlling price cap, enforced after
1999, together with the creation of the new Medicines
Regulatory Board (CMED) after 2003. In addition, the
regulation of “similar” medicines in 2007, also had
effects on the market [12].
With regard to price control, CMED implemented an
annual price readjustment procedure, with a base date in
March, according to a price-cap regulation model. CMED
also controls the entry prices of new medicines in the
Brazilian market according to specific rules by type of
medicine. The manufactory price of an incoming generic
drug should correspond to 65% of the price of the refer-
ence drug at its market launch. The Resolution 2 (2004) of
the CMED provides that, at the time of registration of a
generic product, its price must be at least 35% lower than
the price of the pioneer branded drug to which it refers.
These regulations, impacts on the market dynamic and
differ from other countries [12].
The Generic Medicines Law in Brazil was approved
in February, 1999 (Law 9787) [13], three years after
Brazil began to respect the patent rights of originator
medicines [14]. One year later (February, 2000), the
first generic medicines were approved. Since then,
there have been three types of medicines in the
Brazilian Market. Originators are the innovator prod-
ucts; generics are products considered interchangeable
(bioavailability and bioequivalence must be proven)
with the originator and are commercialized with no
brand name; and ‘similares’ are products marketed
under a trade name, comparable to branded generics
[15] described in the international literature. However,
since 2003, all ‘similar’ medicines were required to
prove their bioequivalence in order to renew their
registration [16].
Since the 1990’s, many regulations aimed at
assuring the quality of the medicines available in the
market have been implemented (Table 1). Encour-
aging market entry of generics was one strategy to in-
crease access to high-quality and low-cost medicines
[17]. Another one was the advent of the Popular
Pharmacy Program, which allows some private phar-
macies to sell medicines at very low costs, with the
largest share of the cost paid by the government. In
2011, the program also started the free provision of
medicines for treating hypertension and diabetes [8].
This paper aims to describe the changes in the
private market for selected originator products,
branded generics, and generics during the first 10
years of the Brazilian generics policy.
Methods
We analyzed longitudinal data on sales of antibiotic,
antidiabetic, and antihypertensive medicines by whole-
salers to private retail pharmacies in Brazil collected
by IQVIA® [18] between 1998 and 2010. The study
design is a descriptive time series [19] with compari-
son series. We made descriptive comparisons of: 1)
percentages of the market share, number of manufac-
tures and sales volume; 2) brand median unit prices
and medicine price ratios for branded generics and
generics using the brand as reference price; 3) sales
volumes of amoxicillin by types of manufacturers: all
types, those who produce only branded generics,
those who produce branded generics and generics
and those who produce only generics and 4) number
and percentage of manufacturers of generics and
branded generics over time.
The data comprise a monthly audit of a universe of
more than 58,000 private pharmacies. The sample de-
sign involves a stratified cluster sample of 11 regions
[20, 21]. The sample size has changed somewhat over
the study period. Since 2009, the sampling units have
been 130 pharmacies (direct sales) and more than
400 wholesalers (indirect sales). The data include total
quarterly sales volume and prices estimates for every
product in the market, projected nationally based on
the sample of pharmacies and wholesalers.
We analyzed the quarterly market share (propor-
tions of the total volume of standard units sold) for
originator, branded generics, and generic products
from the second quarter (Q2) of 1998 through the
first quarter (Q1) of 2010 within three widely used
therapeutic classes (antibiotics, antidiabetics and
antihypertensives). Generics data is available only after
2000, since they did not exist in 1998 and 1999, but
the series of analyses started before (in 1998) to
portrait the pharmaceutical market before the intro-
duction of generics. The standard unit is the smallest
unit of a product (ml, caps or cp). We also examined
quarterly sales volume per capita (calculated by
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dividing sales volumes by annual population) and the
number of manufacturers represented among the
products analyzed.
The pharmaceutical classes selected were antidia-
betics, antihypertensive and antibiotics. Hypertension
and diabetes are chronic diseases that are prevalent
in Brazil and are targeted by specific government
programs to meet the demands of the population in
terms of treatment. Antibiotics belong to a group of
drugs of equal importance, usually of high cost, usu-
ally used in treatments for serious acute problems,
which lead to the need for immediate treatment by
the patient. The choice of these three groups serves
as a model to demonstrate the evolution of the
post-entry market of generics for important health
problems to the Brazilian population and that gener-
ate great interest of the pharmaceutical industry.
Pharmacological groups are classified in the IQVIA®
dataset using the EphMRA/PBIRG Anatomical
Classification that is similar to the WHO/ATC
Classification [22] (Table 2). We included in the ana-
lyses only the molecules included in therapeutic
groups that had any generic products available in the
Brazilian market during the study period and for
which at least one generic manufacturer entered the
market. Within these groups, we included all
chemical entities in which there was at least one
generic alternative on the market during the study
period.
The IQVIA® classification of products includes the
following types of licensing status: licensed brands,
original brands, other brands, patent N/A, and un-
branded. IQVIA® categorizes the relationship between
companies and molecules. To identify the three
groups of medicines of interest, we reclassified the
data, maintaining the same classification for licensed
brands, original brands, and other brand medicines,
and analyzing, on a case by case basis, all medicines
originally classified as patent N/A or unbranded. Our
main objective was to identify which medicines from
Table 1 Chronology of main laws, regulations, and decrees regarding branded generics, generics, and general product quality and
bioequivalence, 1994–2011
Year Branded generics Generics
Law/regulation/contenta Law/regulation/contenta
1994 Normative instruction n°1 - Requirements for the registration of similar
medicines
1996 Law 9279 - Regulates the rights and obligations regarding industrial
property
1999 Law 9787 - Generics Law
Resolution RDC 391 - States that for a product to be registered as
generic there is a need to prove bioequivalence.
Decree 3181 - Regulates Law 9787
2000 Resolution RDC 92 - Similar medicines can be marketed and identified
by trade name or mark that distinguishes the products from those of
other manufacturers
Resolution RE 74 - Approval of the first registrations of generic
medicines
2001 Resolution RES 36 - Similar medicines obligated to start presenting
commercial names; a deadline of 180 days was given to industries to
comply
Resolution RDC 10 - Included a list of medicines that for safety
reasons could not be registered as generic drugs; it is a revision of
the RDC 391.
Resolution RDC 47 - Regulating characteristics of the packaging of
generics
Decree 3961
Updates the definitions of similar, reference and generic drugs
2002 Resolution RDC 157 - Established the requirements for pharmaceutical
equivalence studies for similar drugs
Resolution RDC 84 - Modifies the list of products identified in
resolution RDC 10
2003 Resolution RDC 133 and RDC 134 - Regulations for the registration of
similar medicines requiring products to undergo, by 2014, the same
relative bioavailability and pharmaceutical equivalence testing, required
from the beginning for generic medicines
Resolution RDC 135 - Approves the Technical Regulation for Generic
Drugs; repeals RDC 391 and RDC 84
2007 Resolution RDC 17 - Similar medicines were obligated to present the
same documents for licensing as needed for generics
Resolution RDC 16 - Approves the Technical Regulation for Generic
Drugs; repeals RDC 135
2010 Resolution RES 16 - Amending and repealing legal texts related to the
presentation prior to Anvisa protocol bioequivalence study; repeals
RDC 17.
aLaws, regulations and contents are available at: http://portal.anvisa.gov.br/legislacao
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these two groups were generics, considering that all
generics in Brazil are unbranded. We used three main
sources of information for this reclassification: pack
launch date provided in the IQVIA® dataset; the
Brazilian agency of health regulation (ANVISA –
‘Agência Nacional de Vigilância Sanitária’) list which
includes the date generics were approved to be
commercialized in Brazil; and the Brazilian Website
“Consulta remédios” [23] which includes all Brazilian
medicines available in the market. We then classified
products as: generics, originators and branded ge-
nerics according to the following rules:
a. Generics could only be drawn from the IQVIA®
categories of Patent N/A or Unbranded (medicines
with no brand names);
b. All medicines with IQVIA® pack launch date before
February/2000 maintained the original classification,
because generics were launched in Brazil after this
date;
c. Medicines with missing IQVIA® pack launch date
but within ANVISA list (date in which generics
were approved to be commercialized in Brazil) were
classified as generics;
d. Medicines with missing date on IQVIA® and
ANVISA dataset maintained their original IQVIA®
classification;
e. All medicines within the ANVISA list with an
IQVIA® date after February/2000 were classified
as generics;
f. Medicines missing in the ANVISA list but with
IQVIA® date after February/2000 were checked in
the Consulta Remédios website. If the medicine was
present, it was reclassified as generic, otherwise we
kept the original IQVIA® classification.
For the price analysis, we compared the wholesaler
prices of originator or licensed brand products with
their generic and brand generic versions for the years
2002, 2006 and 2010. We used the unit price (US$)
available for the first quarter of each year. We calcu-
lated the ratio (price of generic or branded generic
divided by the reference price) of the unit prices for
each molecule, for each manufacturer (generic and
branded generic) that had a price available and we
present the median value of the ratio in each period.
The reference price was the original brand price; the
licensed brand price was used when the brand was
not available. The ratios are presented as percentages
of the reference price. We only present the medicines
for which we had price data for the three selected
years and had at least price information for generics
or branded generics for two of these years.
We selected oral formulations only for products that
had oral formulations (whether or not they also had
injectable formulations); if a molecule did not have an
oral formulation, which happened for some antibiotics,
we used only the injectable formulations.
Analyses were carried out using the statistical soft-
ware Stata 10.0 and Microsoft Excel 2010. The use of
the data was authorized by IQVIA®. The data are con-
tained in a secondary database and do not involve
human research subjects. The identities of the retail
pharmacies and wholesalers in the sample were not
part of the dataset.
Results
We obtained data on 8559 products marketed in Brazil
between 1998 and 2010. Of these, 2825 were systemic anti-
bacterial (25.1% broad spectrum penicillin, 17.6% macro-
lide, 17.5% cephalosporin, 14.7% fluoroquinolone, 25.1%
others), 448 medicines were used to treat diabetes (31.3%
sulphonylurea, 25.5% biguanide, 25.9% insulin, 17.3%
others) and 2113 to treat hypertension (5.3% methyldopa,
13.2% diuretic, 19.2% beta blocking agent, 16.7% calcium
antagonist, 45.6% renin-angiotensin system agent).
Longitudinal data on the market share, sales volume
per capita, and number of manufacturers for the three
pharmacological groups in the study are presented in
Fig. 1. Results are described below for each group of
medicines. Table 4 in Appendix shows trends in the
numbers and percentages of manufacturers of generics,
branded generics, or both over time.
For the three groups of medicines, the number of
manufacturers of branded generics decreased from 2002
to 2010, while the number of manufacturers of generics
increased. For antibiotics and antihypertensive, the
number of manufacturers that produce both branded
generics and generics has also increased over time.
Table 2 Pharmacological groups and subgroups of medicines used in the study
Pharmacological Group Pharmacological Sub-Groupa
Anti-infectives for systemic use subgroup J01/J1 – Antibacterials for systemic use/systemic antibacterials
Alimentary tract and metabolism
medicines
subgroup A10 – Drugs used in diabetes
Cardiovascular system medicines subgroups: C02/C2 – Antihypertensive (methyldopa); C03/C3 – Diuretics; C07/C7 – Beta blocking agents; C08/C8
– Calcium channel blockers /Calcium antagonists; C09/C9 – Agents acting on the renin-angiotensin system)
aACT/EphMRA codes for pharmacological sub-groups included in the study
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These trends were consistent in almost all subgroups of
medicines included in the analysis.
Systemic antibiotics
Almost all antibiotics for systemic use have generics in
the market. We analyzed the seven groups with the lar-
gest sales volumes (almost 75% of the sample): oral and
parenteral broad-spectrum penicillin; oral and parenteral
fluoroquinolone; oral and parenteral cephalosporin, and
macrolide.
Prior to the entry of generic products to the mar-
ket, originators and branded generics had approxi-
mately equal market share (Fig. 1a). Market share
changed very rapidly after the introduction of the first
generic antibiotics in 2000-Q2. One year later, ge-
nerics (43%) had overtaken both originators (20%)
and branded generics (37%) in terms of market share.
After initial declines, branded generic market share
has remained relatively stable after 2001-Q4. The
market share of originator antibiotics has declined
consistently over time following introduction of
generics, representing less than 5% of the market by
the end of the study, compared to 60% for generics
and 35% for branded generics. None of the
manufacturers producing generic antibiotics were also
manufacturers of originators.
There were consistently more manufacturers
producing branded generics than generics or originators
(Fig. 1b). However, after rising until 2002-Q3, the
number of branded generics manufacturers remained
stable until 2005-Q3 and declined afterwards. The
number of manufacturers producing generic antibi-
otics, on the other hand, continued to rise during the
whole period under study (Fig. 1b).
Generic antibiotic sales volume per capita has
steadily increased from their introduction to the end
of the study period, while the per capita sales volume
of original brands has consistently decreased (Fig. 1c).
After a decline following the launch of generics in
the market, branded generics sales volume per capita
has risen since 2004-Q2 but continued to remain
below that of generics.
Figure 2 presents the amoxicillin case, as an example,
which illustrates the general pattern of changes in the
pharmaceutical market regarding the manufactures
producing generics; similar trends are found for other
medicines and therapeutic classes. Sales volume has in-
creased overall (A) and among manufactures that
Fig. 1 Quarterly proportion of market share (a-antibiotic; d-antidiabetic; g-antihypertensive) number of manufacturers (b-antibiotic; e-antidiabetic; h-
antihypertensive), and sales volumes per capita (c-antibiotic; f-antidiabetic; i-antihypertensive) of antibiotics, antidiabetics and antihypertensive
medicines in the ATC4 categories that have generic products in Brazil, 1998–2010
Bertoldi et al. Journal of Pharmaceutical Policy and Practice           (2019) 12:18 Page 5 of 12
produce branded generics and generics (C) but declined
among those focusing their production on branded ge-
nerics (B) or generics only (D).
As shown in Table 3, for approximately 50% of the
antibiotic molecules analyzed, the branded generics and
generics had lower prices than the originators. There
was no consistent pattern of the percentage changes in
prices. In 2010, some generics became more expensive
than branded generics (Table 3).
For the cephalosporins, in general, branded generics
had higher prices than originators. In the 2010, cefazolin
branded generic had a price more than 2 times higher
(262%) than the originator (Table 3).
Finally, branded generic prices have fallen substantially
over time for all macrolides. The price of generics in-
creased over time, eventually exceeding the price of the
originator medicines for clarithromycin (2006 and 2010)
and azithromycin (2006) (Table 3).
Medicines used in diabetes
Antidiabetics with generics were sulphonylureas and
biguanides which represented 56.7% of all antidiabetic
medicines.
Prior to the appearance of generics, originators
dominated the market, corresponding to around 85%
of sales volume (Fig. 1d). From 1998 to the 2001-Q3,
there were concomitant rises in the market share of
branded generics and declines in the sales of origina-
tors. After the introduction of generics in the market,
the market share of originators continued to decline,
while branded generics no longer increased as
generics began to increase. However, the increase in
generic antidiabetic market share was more gradual
than for antibiotics, and it did not surpass 50% until
2007. By 2010, generics corresponded to half of all
sales, branded generics to just over 30%, and origina-
tors had fallen to below 20%.
There was a rapid rise in the number of manufac-
turers producing branded generics in the antidiabetic
class, and this number stabilized from 2005-Q3 on-
wards (Fig. 1e). Following the introduction of generic
antidiabetic products in the market in 2001-Q3, there
was a consistent increase in the number of manufac-
turers producing them. Among the manufacturers of
the three molecules included in the study, one also
started to produce a generic equivalent in 2010-Q1.
Few manufacturers of antidiabetics produced generics
and branded generics simultaneously.
Generic sales volumes per capita have increased stead-
ily since mid-2001 when the first generics entered the
market, while there has been a gradual decline in the
sales volumes of originators that began even prior to the
Fig. 2 Sales volumes (IQVIA standard units) of amoxicillin by types of manufacturers: a all manufacturers; b manufacturers who produce only
branded generics (N = 33); c manufacturers who produce branded generics and generics (N = 12) and d manufacturers who produce only
generics (N = 8)
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Table 3 Brand or licensed brand median unit prices (US$) and medicine price ratios for branded generics and generics considering
the brand or licensed brand as reference price, for antibiotics, antidiabetics and antihypertensives, in Brazil, 2002, 2006 and 2010
Selected medicines 2002 2006 2010
Originator Branded
generics
Generics Originator Branded
generics
Generics Originator Branded
generics
Generics
Antibiotics
Penicillins
Amoxicillin a, c 1.02 72.0% 24.9% 1.48 54.9% 38.6% 1.53 46.9% 44.8%
Amoxicillin+Clavulanic acid a, c 2.03 83.9% 66.8% 3.61 78.5% 49.1% 3.82 64.2% 75.4%
Ampicillin a, d 1.06 75.2% 50.8% 1.49 49.4% 49.5% 1.82 35.6% 42.7%
Fluoroquinolones
Ciprofloxacin a, c 2.71 72.2% 100.3% 10.75 19.1% 31.2% 12.33 15.0% 19.6%
Levofloxacin a, d 6.01 * * 9.26 45.1% 54.4% 11.63 39.4% 43.1%
Norfloxacin a, d 1.50 55.8% 59.4% 1.94 55.9% 60.0% 2.34 53.0% 57.3%
Cephalosporins
Cefaclor a, d 1.93 148.8% * 2.39 144.8% 107.6% 3.57 * 72.2%
Cefadoxil a, c 3.49 34.8% 43.6% 4.92 29.8% 36.9% 3.07 32.5% 67.1%
Cefalexin a, d 1.53 78.2% 43.3% 1.74 81.7% 62.7% 2.13 64.0% 54.9%
Cefuroxime axetil b, c 4.08 * 46.0% 4.99 * 42.5% 6.01 * 61.4%
Cefalotin b, d 2.79 106.7% 114.3% 3.67 94.0% 80.7% 4.62 101.3% 65.7%
Cefazolin b, d 5.58 110.4% * 6.38 60.6% * 4.29 262.2% 93.3%
Cefepime b, c 19.10 * * 25.05 171.3% 71.2% 57.79 87.8% 69.2%
Ceftazidime b, c 29.97 56.6% * 31.63 38.9% 47.2% 49.94 30.0% 30.0%
Ceftriazone b, c 30.73 49.5% 25.4% 45.94 44.2% 23.5% 52.85 30.3% 30.0%
Macrolides
Azitromycin a, d 6.91 68.4% 99.3% 6.38 80.6% 116.8% 7.62 48.5% 83.1%
Claritromycin a, d 3.12 116.1% 82.1% 3.43 88.6% 118.2% 4.11 64.0% 119.3%
Clindamycin a, c 2.00 97.6% 60.8% 2.84 58.6% 53.9% 3.41 53.0% 52.8%
Erythromycin a, d 0.64 141.5% * 0.71 139.8% * 0.81 85.8% 111.7%
Antidiabetics a, c
Glibenclamide 0.16 57.9% 66.9% 0.20 63.9% 63.7% 0.25 53.7% 63.5%
Glimepiride 0.38 161.7% * 0.53 118.1% 117.0% 0.99 74.2% 78.8%
Antihypertensives a
Methyldopa c 0.37 167.3% 102.1% 0.48 123.7% 78.4% 0.59 108.5% 72.3%
Diuretics
Spironolacton c 0.41 * * 0.52 73.7% 64.4% 0.57 71.9% 65.7%
Furosemide c 0.15 106.8% 86.0% 0.11 218.5% 183.6% 0.12 174.6% 139.4%
Chlorthalidone c 0.19 88.3% * 0.25 71.4% 66.0% 0.27 65.5% 79.7%
Amiloride+hydrochlorothiazide
c
0.20 97.1% * 0.26 92.1% 68.1% 0.30 94.7% 64.7%
Betablockers
Atenolol c 0.44 68.9% 59.0% 0.61 53.3% 46.8% 0.70 46.9% 41.5%
Carvedilol c 1.06 65.3% * 1.57 38.1% 48.8% 1.91 32.7% 46.8%
Metoprolol c 0.51 * 45.1% 0.36 * 89.2% 0.42 * 87.6%
Propranolol c 0.11 63.0% * 0.16 58.7% 56.8% 0.18 60.3% 57.1%
Sotalol c 0.85 * 79.5% 1.33 65.4% 71.4% 1.58 75.8% 71.0%
Atenolol+Chlorthalidone c 0.60 71.0% * 0.83 58.7% 52.2% 0.94 55.3% 49.5%
Bertoldi et al. Journal of Pharmaceutical Policy and Practice           (2019) 12:18 Page 7 of 12
introduction of generics (Fig. 1f ). The sales volumes of
branded generics declined slightly from 2001 to 2006,
but sales have risen steadily since that period.
The prices of glimepiride branded generics
experienced important reductions over time (Table 3),
especially after the introduction of generics.
Glibenclamide, on the other hand, experienced only
small fluctuations in prices, both for generics and
branded generics. For both antidiabetic medicines, the
prices of branded generics and generics were quite
similar during the period analyzed.
Medicines used in hypertension
The market share for both branded generics and ge-
nerics to treat hypertension tended to increase until
2006-Q1 (Fig. 1g). After that, market share of generics
continued to increase, reaching a high of 40%, whereas
branded generics market share stabilized at around 35%.
Originators declined consistently, reaching a low of 23%
market share.
In 2000-Q2, the first antihypertensive generics were
launched in the market, and the number of manufac-
turers producing generics increased steadily over time.
Nevertheless, the number of manufacturers producing
branded generic has remained consistently higher
than generics. From 2006-Q2 onwards, there was a
decline in the number of manufacturers producing
branded generics (Fig. 1h). Among the five ATC2
groups of medicines used to treat hypertension in the
study, we identified 30 molecules with generics. Only
two manufacturers producing originators also pro-
duced generics (furosemide and ramipril, both from
the same manufacturer). There were 21 molecules for
which the same manufacturer produced generics and
branded generics.
Antihypertensive originator sales volumes per capita
decreased rapidly during the entire period, while per
Table 3 Brand or licensed brand median unit prices (US$) and medicine price ratios for branded generics and generics considering
the brand or licensed brand as reference price, for antibiotics, antidiabetics and antihypertensives, in Brazil, 2002, 2006 and 2010
(Continued)
Selected medicines 2002 2006 2010
Originator Branded
generics
Generics Originator Branded
generics
Generics Originator Branded
generics
Generics
Calcium antagonists
Amlodipine c 1.51 52.7% 50.5% 1.88 36.9% 41.6% 2.11 34.4% 46.2%
Diltiazem d 0.45 119.6% 29.1% 0.55 140.2% 36.0% 1.01 101.1% 34.7%
Felodipine c 1.20 * * 1.62 76.5% 84.1% 1.92 * 50.1%
Verapamil c 0.40 70.1% 91.4% 0.57 58.2% 52.1% 0.62 42.0% 56.8%
ACE inhibitors
Captopril c 0.58 54.0% 57.9% 0.87 38.5% 44.7% 1.09 30.6% 41.1%
Enalapril c 0.97 39.4% 41.9% 0.46 97.9% 113.8% 0.33 146.2% 170.5%
Lisinopril c 0.82 59.0% 61.6% 1.09 59.3% 62.3% 1.50 45.5% 53.7%
Ramipril c 0.66 122.6% * 2.66 40.7% 42.5% 3.23 30.9% 32.7%
Captopril+ hydrochlorothiazide
c
1.12 68.2% * 1.57 73.1% 58.6% 1.79 46.4% 60.4%
Enalapril+ hydrochlorothiazide c 1.04 65.3% * 1.36 54.5% 61.0% 0.93 87.8% 107.7%
Lisinopril+ hydrochlorothiazide
c
1.10 131.4% * 1.40 60.9% 108.2% 1.60 69.0% *
Ramirpil+ hydrochlorothiazide c 2.18 48.1% * 3.08 46.6% * 3.49 37.4% 44.8%
Losartan d 1.76 62.9% * 2.48 40.2% 36.4% 1.06 68.4% 63.5%
Losartan+ hydrochlorothiazide d 1.76 75.2% * 2.49 35.6% 55.1% 1.54 61.8% 82.1%
The time points are the first quarter of the respective year
*no unit price for generic or branded generic available
aOral presentations
bInjectable preparations
cOriginal brand
dLicensed brand
Medicine price ratios for branded generics and generics considering the brand or licensed brand as reference price with percentages higher than 100% were
highlighted in boldface
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capita sales volumes of branded generics and generics
increased. After 2007-Q2, sales volumes of generics
exceeded those of branded generics (Fig. 1i).
Price trends over the years for the subclasses had very
different patterns (Table 3). For instance, methyldopa
branded generic prices have always been higher than those
of the originator. Generics started with a price similar to
originators but experienced a reduction overtime.
In the diuretics, except for furosemide, the
originator prices have risen. For furosemide, branded
generic versions have always had a higher price than
the originator. Even though the price ratio for ge-
nerics is not as high as it is for the branded generics,
it was still higher than the originator price.
Betablockers did not experience meaningful fluctua-
tions in prices during the period analyzed, except for
metoprolol. For this medicine, which had no branded
generics available in the Brazilian market, the generics
price increased in 2006 to 89.2% of the originator’s
price and remained mostly the same in 2010.
The calcium antagonists subclass exhibited two
different patterns of price variation. For amlodipine and
verapamil as examples of the first pattern, branded ge-
nerics and generics had price reductions while origina-
tors had price increases from 2002 to 2010. For
diltiazem as an example of the second pattern, branded
generics were the most expensive version, even with in-
creases in the originator’s price, and prices were about
equal in 2010.
Finally, the ACE inhibitors experienced interesting
patterns of price variations from 2002 to 2010. Overall,
originator prices increased from 2002 to 2010, except for
enalapril; in contrast, enalapril + hydrochlorothiazide,
losartan and losartan + hydrochlorothiazide had lower
originator prices in 2010.
Discussion
The introduction of generics in the Brazilian market led
to large decreases in the sales volumes of originators in
the three therapeutic classes examined. Changes in
market share started as soon as the first generics in
each class were introduced into the market. After 10
years of the generics policy, generics represented the
largest market share in all classes, although the propor-
tion varied across pharmacological groups and mole-
cules. The speed of the transition to generics has varied
by class, with the shift occurring most rapidly for anti-
biotics, followed by antidiabetics and antihypertensives.
The introduction of generics was much more impactful
for antibiotics than for the other groups. It is possible
that the growth of generics is related to whether the
drugs are used to treat chronic versus acute illnesses.
For a country unused to generics, it may be more diffi-
cult to change use of established products for chronic
therapy. Repeated prescriptions and purchases without
a prescription will tend to be of the same rather than
another product with a different name [24–26].
Several manufacturers that originally produced
branded generics have started to produce generics of
the same molecules, accounting for 25, 12 and 20%
of the manufacturers of antibiotics, antidiabetics and
antihypertensives, respectively. This is likely an at-
tempt to retain or increase market share [27]. A good
example is amoxicillin where sales volumes increased
overall and for manufacturers producing both branded
generics and generics but declined for manufacturers
producing branded generics only. Furthermore, the
sales volumes of manufacturers producing generics
only has decreased over time.
We expected that the number of branded generics in
the market would continue to decline over time; how-
ever, despite increases in generic market share over the
years, by 2011 branded generics continued to be the
most widely sold in Brazil [28].
The generic law occurred in Brazil in a historical
moment where counterfeit medicines were increasing
[29]. Generic medicines brought the possibility of
having more affordable medicines with the same
quality that the original. Prior to the approval of the
generic law, local pharmaceutical companies could
copy originator medicines without presenting any
therapeutic equivalence test [30]. With the introduc-
tion of generics, there was an increase in the inspec-
tion of good manufacturing practices [29, 30]. Thus,
the relevance of our finding, that even with increases
costs due to the need of bioequivalence tests to regis-
ter the generics, the pharmaceutical market turned in
this direction, with the reduction of branded generics.
Diverse interests of public and private sector stake-
holders might shaped generic drug policy and its
implementation [30]. Considering the international
context, in Brazil we presented similar trends as
others low and middle-income countries (LMICs). The
market share of originators substances had the largest
decrease over time when compared to the market share of
their counterpart generic versions [28].
By law, it is mandatory that generic medicines
enter the market at least 35% below the price of the
originator [31]. This regulation is not applicable to
branded generics. However, our results do not always
show this relationship. Instead, we observe cases in
which generics were more expensive than originators.
This is likely because the price regulation in Brazil
applies to ceiling prices, the maximum prices allowed
for each medicine to be sold by wholesalers to
pharmacies and by pharmacies to consumers. These
ceiling prices are established at the time of registra-
tion. Our data reflect selling prices, which are lower
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than these ceiling prices [17, 32]. Furthermore, there
is no legal mechanism to reduce these ceiling prices
over time [32].
When generic prices are higher than originator
prices [17, 33], wholesalers may be applying discounts
to originators and branded generics to retain market
share in the face of lower cost generics. With the increas-
ing acceptance of generics by prescribers and consumers, it
is possible that generics become more expensive due to a
public image of having better quality than branded
generics.
In Brazil, the prevalence of generic medicines use
was 45.5% in 2014. In the private sector, a relevant
part of the population is choosing generic medicines,
due to its availability as an option for the most medi-
cines used by the population, which is an evidence
that the generic law in Brazil has increase access to
medicines [34].
Our study has several limitations. It is possible that
some misclassification took place in the process of re-
classifying products from the IQVIA® categories. Rea-
sons may include: missing ANVISA date or IQVIA®
launch date, ANVISA date that occurs after the
IQVIA® launch date, or ambiguity in product identity
due to mergers of manufacturers. Some products may
also have been misclassified in the IQVIA® dataset.
To minimize misclassification, we used consistent
rules for classification. Another limitation is that
IQVIA® data represent only a sample of suppliers and
facilities; however, this information is submitted to a
validation process to assure the accuracy of the na-
tional estimates. An additional limitation is that
IQVIA® collects price data from wholesalers, which
may not reflect commercial deals further along the
supply chain, such as discounts to the pharmacy.
These discounts mean that the originator or branded
generics can be sold at prices more similar to that of
the generics. The sales data may not only reflect the
effect of policy per se but also the effect of commer-
cial reactions to that policy.
Conclusion
In conclusion, entry of generic products following the
Brazilian Generic Medicines Law resulted in import-
ant reductions in market share for originator
products, price reductions for branded generics and
originators, and increases on the total number of
manufactures in the therapeutic classes selected.
Speed of market appearance and uptake of generics
varied by pharmacological group. The 1999 Generics
Appendix
Table 4 Number and percentagec of manufacturers of generics and branded generics by licensure type over timeb
Selected medicinesa 2002 2006 2010
Branded
generics
Generics Generics +
Branded
generics
Branded
generics
Generics Generics +
Branded
generics
Branded
generics
Generics Generics +
Branded
generics
N % N % N % N % N % N % N % N % N %
Antibiotics
Penicillins 36 78.3 3 6.5 7 15.2 32 68.1 6 12.8 9 19.1 15 41.7 7 19.4 14 38.9
Fluoroquinolones 29 85.3 2 5.9 3 8.8 36 69.2 9 17.3 7 13.5 22 47.8 12 26.1 12 26.1
Cephalosporins 19 73.1 2 7.7 5 19.2 20 57.1 8 22.9 7 20 11 39.3 7 25 10 35.7
Macrolides 29 82.9 1 2.9 5 14.3 31 72.1 2 4.7 10 23.3 23 57.5 7 17.5 10 25
Antidiabetics
Glibenclamide 11 91.7 1 8.3 0 0 15 71.4 5 23.8 1 4.8 12 57.1 8 38.1 1 4.8
Glimepiride 2 100 0 0 0 0 9 69.2 3 23.1 1 7.7 6 35.3 9 52.9 2 11.8
Metformin 4 66.7 1 16.7 1 16.7 13 56.5 9 39.1 1 4.3 13 41.9 15 48.4 3 9.7
Antihypertensives
Methyldopa 12 92.3 1 7.7 0 0 13 76.5 2 11.8 2 11.8 7 63.6 2 18.2 2 18.2
Diuretics 20 90.9 1 4.5 1 4.5 27 77.1 5 14.3 3 8.6 22 68.8 6 18.8 4 12.5
Betablockers 13 76.5 2 11.8 2 11.8 17 60.7 6 21.4 5 17.9 15 48.4 9 29 7 22.6
Calcium antagonists 18 81.8 2 9.1 2 9.1 24 63.2 8 21.1 6 15.8 16 48.5 11 33.3 6 18.2
ACE inhibitorsd 26 78.8 3 9.1 4 12.1 37 71.2 8 15.4 7 13.5 33 62.3 12 22.6 8 15.1
aIncluded are only antidiabetic, antihypertensive and antidiabetic molecules which had generics in the market during the study period
bTime points are the first quarter of the respective year
cDenominators are the total number of manufacturers of branded generics and generics in each period
dACE = Angiotensin-converting enzyme
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Law changed the dynamics of the pharmaceutical
market during its first 10 years of implementation.
Future studies should examine continuing changes in
the market as consumers gain greater confidence in
generic products and manufacturers develop new
marketing strategies.
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